Fig 1. Associations between the M-CHARTS score at baseline and 12 months after initiating intravitreal ranibizumab therapy.
The M-CHARTS score at baseline is significantly correlated with the M-CHARTS score 12 months after initiating intravitreal ranibizumab therapy for macular edema associated with branch retinal vein occlusion (r = 0.503, P = 0.003). The M-CHARTS score used in analyses was the higher score among the vertical and horizontal scores.